Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease

American Heart Journal
Christopher P CannonMatthew R Reynolds

Abstract

In patients with atherosclerotic cardiovascular disease (ASCVD), guidelines recommend statins as first-line lipid-lowering therapy (LLT) with addition of nonstatin agents in those with persistently elevated low-density lipoprotein cholesterol levels. To estimate the cardiovascular (CV) risk reduction implications of treatment intensification, we used a previously reported simulation model with enhancements. An ASCVD cohort was developed from a US claims database. A Cox model was used to estimate baseline risk of CV events: myocardial infarction, ischemic stroke, unstable angina hospitalization, elective coronary revascularization, or cardiovascular death. Patients were sampled with replacement (bootstrapping) and entered the simulation model, which applied stepwise LLT intensification logic, with a goal of achieving low-density lipoprotein cholesterol less than 70 mg/dL at each step. CV risk reduction assumptions were based on published data. Two treatment intensification scenarios were investigated: ideal and real-world (which accounted for statin intolerance, nonadherence, and payer restrictions). In a cohort of 1,000 patients with ASCVD, approximately 813 (809-818) would require treatment intensification with LLT under an id...Continue Reading

References

Sep 22, 1999·Journal of General Internal Medicine·L A PetersenJ Daley
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jan 30, 2016·Journal of the American College of Cardiology·Sabina A MurphyEugene Braunwald
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Nov 8, 2018·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN ODYSSEY OUTCOMES Committees and Investigators
Nov 15, 2018·Journal of the American College of Cardiology·Michael SzarekUNKNOWN ODYSSEY OUTCOMES Committees and Investigators

❮ Previous
Next ❯

Citations

Jul 29, 2021·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Vivencio BarriosÁngel Cequier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.